Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chlorogenic acid in preparation of medicines for treating parkinson disease

A technology for Parkinson's disease and chlorogenic acid is applied in the field of use of chlorogenic acid in the preparation of a drug for treating Parkinson's disease, and can solve the problems of striatal DA deficiency, basal ganglia neuromodulation disorder and the like, and achieve a pathological state Effects of improving and treating, inhibiting substantia nigra apoptosis and reducing oxidative stress damage

Inactive Publication Date: 2015-05-27
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main clinical pathological change is the selective death and loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc) of the midbrain, resulting in insufficient DA in the striatum, which leads to the disorder of the neuromodulatory function of the basal ganglia. etiology, so far unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chlorogenic acid in preparation of medicines for treating parkinson disease
  • Application of chlorogenic acid in preparation of medicines for treating parkinson disease
  • Application of chlorogenic acid in preparation of medicines for treating parkinson disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1. In vivo pharmacodynamic investigation of chlorogenic acid on Parkinson's model mice

[0042] Experimental Materials

[0043] 1.1 Experimental reagents and instruments

[0044] Chlorogenic acid (Sichuan Jiuzhang Biotechnology Co., Ltd.), rotenone (SIGMA), dimethyl sulfoxide (DMSO, SIGMA), corn oil (Shandong Luhua Group Co., Ltd.), mouse α-SYN monoclonal antibody, SABC immune tissue Chemical kits were purchased (Wuhan Boster Company), mouse tyrosine hydroxylase monoclonal antibody, rabbit microtubule-associated protein light chain 3 polyclonal antibody (Biyuntian), malondialdehyde content and superoxide dismutase, gluten Glutathione peroxidase and catalase kit (Nanjing Jiancheng Biological Engineering Co., Ltd.). The rest of the reagents were of domestic commercially available analytical grade.

[0045] 1.2 Animal modeling and grouping

[0046] In this experiment, a mouse model of Parkinson's disease was established by subcutaneous injection of rotenone. T...

Embodiment 2

[0084] Example 2. Investigation of the effects of chlorogenic acid on the HMGCS2 gene and the corresponding trihydroxytrimethyl-CoA synthetase 2 activity, ketone body content in the body and the apoptosis of substantia nigra cells in Parkinson's model mice

[0085] 1. Experimental materials

[0086] 1.1 Experimental reagents and instruments

[0087] Chlorogenic acid, Madopar (dopasrazine tablets, Shanghai Roche Pharmaceutical Co., Ltd.), microplate reader (Rebo mk3 microplate reader from Finland), real-time fluorescent quantitative PCR instrument (Applied Biosystems, Inc.; ABI), total RNA Extraction Kit (Tiangen Biochemical Technology Co., Ltd.), TIANScript cDNA First Strand Synthesis Kit (Tiangen Biochemical Technology Co., Ltd.), Annexin-FITC-PI Double Staining Apoptosis Detection Kit (Biyuntian), Mouse Ketone Body Detect ELISA kit (Sigma), flow cytometer (Beckman), etc.

[0088] 1.2 Animal model and grouping

[0089] Of 30 BALB / C mice, 10 were randomly selected as the no...

Embodiment 3

[0128] Embodiment 3: Prepare freeze-dried powder injection with chlorogenic acid

[0129] 1. Extraction of chlorogenic acid:

[0130] The chlorogenic acid crude drug used in this example is extracted and purified from Flos Lonicerae, with a purity of 99.52%.

[0131] 2. Preparation of chlorogenic acid freeze-dried powder injection

[0132] 2.1 Prescription:

[0133]

[0134] Completely dissolve the above prescription in water for injection, filter, and fine filter with a 0.22 μm sterilizing microporous membrane, adjust the pH, and make a total of 1000 2ml powder injections according to the routine operation of sterile powder injections, each Contains chlorogenic acid 40mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of chlorogenic acid in preparation of medicines for treating a parkinson disease. The chlorogenic acid is beneficial to reduction of the toxicity of substantia nigra and striatum neurons and activation of the autophagy activity of substantia nigra and striatum neurons in a midbrain, beneficial to adjustment of blood ketone content of a parkinson disease mice model, and beneficial to inhibition of apoptosis of substantia nigra cells in the parkinson disease mice model, and plays positive improvement and treatment roles in symptoms, pathology and the like of the parkinson disease.

Description

technical field [0001] The invention belongs to the new medical application of chlorogenic acid, in particular to the application of chlorogenic acid in preparing medicine for treating Parkinson's disease. Background technique [0002] Parkinson's disease (PD), also known as parkinsonism, is one of the most common neurodegenerative diseases. The main clinical pathological change is the selective death and loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc) of the midbrain, resulting in insufficient striatal DA, which leads to the disorder of basal ganglia neuromodulatory function. The etiology is as yet unknown. However, studies have confirmed that the disease is closely related to oxidative stress and mitochondrial dysfunction. Therefore, alleviating oxidative stress damage can be used as a drug target to treat Parkinson's disease. In addition, the latest research shows that ketone bodies can improve the clinical symptoms of neurodegenerative diseases...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61P25/16
CPCA61K31/216
Inventor 张洁张梦甜黄望
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com